-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Unicycive Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2021 to Q3 2024.
- Unicycive Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $605K, a 34.9% decline year-over-year.
- Unicycive Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $2.32M.
- Unicycive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1.77M, a 68.8% increase from 2022.
- Unicycive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1.05M, a 8.39% increase from 2021.
- Unicycive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $966K, a 316% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)